Anti-inflammatory treatment after discharge home from the emergency department in adults with acute asthma - 12/08/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Key words : Asthma exacerbation, acute asthma, emergency department, discharge medications, corticosteroids, leukotriene modifiers
Abbreviations used : ED, ICS, IMCS, OCS, RCT
Plan
Disclosure of potential conflict of interest: J. A. Krishnan has declared that he has no conflict of interest. R. Nowak has declared that he has no conflict of interest. S. Q. Davis has declared that he has no conflict of interest. M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. |
|
This article is part of the Joint Task Force Report: Supplemental Recommendations for the Management and Follow-up of Asthma Exacerbations, an official statement of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Emergency Medicine (AAEM), and the American Thoracic Society (ATS). It was approved by the AAAAI Board of Directors, January 16, 2008, the AAEM Board of Directors, January 14, 2008, and the ATS Board of Directors, March 13, 2009. |
|
The Joint Task Force Report is copublished in the Journal of Allergy and Clinical Immunology, the Journal of Emergency Medicine, and the Proceedings of the American Thoracic Society. |
Vol 124 - N° 2S
P. S29-S34 - août 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?